Abstract
BackgroundIn Thailand, the proportion of Plasmodium vivax infection has become equal to Plasmodium falciparum. Reports of a trend of gradual decline of in vitro sensitivity of P. vivax to chloroquine in some areas of the country, together with accumulating evidences of chloroquine resistance P. vivax in other parts of the world, emphasize the need for closely and continuously monitoring clinical efficacy in conjunction with in vitro sensitivity of P. vivax isolates.MethodsThe study was conducted at Mae Tao clinic for migrant workers, Tak Province during March 2008 - August 2009. A total of 130 patients (17 Thais and 113 Burmeses; 64 males and 66 females) with mono-infection of P. vivax malaria, aged between 15-60 years and weighing more than 40 kg, were included in the study. Patients received treatment with chloroquine (2,000 mg chloroquine phosphate over three days) and the anti-relapse drug primaquine (15 mg for 14 days). In vitro sensitivity of P. vivax isolates was evaluated by schizont maturation inhibition assay.ResultsAll patients showed satisfactory response to treatment. The cure rate was virtually 100% within the follow-up period of 42 days. Neither recurrence of P. vivax parasitaemia nor appearance of P. falciparum occurred during the investigation period. In vitro data showed a stable sensitivity of chloroquine in this area since 2006. Geometric mean and median (95% CI) values of IC50 for chloroquine were 100.1 and 134.7 (1.1-264.9) nM, respectively.ConclusionIn vivo results suggest that the standard regimen of chloroquine was still very effective for the treatment of blood infections with P. vivax in the Thai-Myanmar border area. In vitro sensitivity data however, raise the possibility of potential advent of resistance in the future. Regular monitoring of the chloroquine sensitivity of P. vivax is essential to facilitate the early recognition of treatment failures and to expedite the formulation of appropriate changes to the drug policy.
Highlights
In Thailand, the proportion of Plasmodium vivax infection has become equal to Plasmodium falciparum
The objectives of the present study were to assess in vivo efficacy of first-line regimen of chloroquine given with primaquine, and in vitro susceptibility of P. vivax isolates in areas along the Thai-Myanmar border to chloroquine and the new antifolate WR99120
Clinical efficacy A total of 130 patients with P. vivax malaria were included in the study and all had completed a 42 days follow-up period
Summary
In Thailand, the proportion of Plasmodium vivax infection has become equal to Plasmodium falciparum. The accumulating reports of chloroquine resistance P. vivax in other parts of the world during the past three decades including Papua New Guinea [8,9,10,11], Indonesia [12], Irian Jaya [13,14,15,16], Guyana South America [17], Peru [18], Colombia [19], India [20], Myanmar [21,22,23], Vietnam [24], Turkey [25], and Ethiopia [26] emphasize the need for closely and continuously monitoring clinical efficacy in conjunction with in vitro sensitivity of P. vivax isolates.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.